Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-x4r87 Total loading time: 0 Render date: 2024-04-28T19:51:30.126Z Has data issue: false hasContentIssue false

13 - Clinical uses of botulinum toxin

Published online by Cambridge University Press:  02 December 2009

By
John Elston
Edited by
Anthony B. Ward  and
Michael P. Barnes
John Elston
Affiliation:
Oxford Eye Infirmary, Radcliffe Infirmary, Oxford, UK
Anthony B. Ward
Affiliation:
University Hospital of North Staffordshire
Michael P. Barnes
Affiliation:
Hunters Moor Regional Neurological Rehabilitation Centre
Get access

Summary

Ophthalmological uses

Introduction

Botulinum toxin targets the cholinergic neuromuscular complex with exquisite precision producing dose dependent muscle weakness. The concept of using this property therapeutically was an ingenious and bold one, and it came from a thoughtful and innovative ophthalmologist over 30 years ago. Working at the time on extraocular muscle electromyography (EMG) Alan Scott of the Smith Kettlewell Eye Research Foundation was exploring the treatment potential of the ability to locate a needle tip at or near the motor point of extraocular muscles. Using an EMG guided injection technique could enable focal delivery of a drug – for example local anaesthetic – to modify muscle function. The ideal drug would need to remain localized at the injection point and have an effect on muscle function only, without inducing inflammation or scarring, either temporarily enhancing or more probably reducing function, over a predictable time frame. Full recovery of extraocular muscle function would be necessary to restore normal eye movement. During the period of induced muscle underactivity it was hypothesized that the balance between two opposing extraocular muscles (agonist: antagonist balance) would be altered in such a way that a permanent change in the relative position of the two eyes would be achieved after the effect of the drug had worn off. This created the possibility of treating misalignment of the eyes (strabismus or squint) by non-surgical means.

Type
Chapter
Information
Clinical Uses of Botulinum Toxins , pp. 262 - 281
Publisher: Cambridge University Press
Print publication year: 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Scott, A. B., Rosenbaum, A. and Collins, C. C. (1973). Pharmacological weakening of extra-ocular muscles. Invest. Ophthalmol. Vis. Sci., 12, 924–7.Google Scholar
Lennerstrand, G., Nordbo, O. A., Tian, S., Eriksson-Derouet, B. and Ali, T. (1998). Treatment of strabismus and nystagmus with botulinum toxin type A. An evaluation of effects and complications. Acta Ophthalmol. Scand., 76(1), 27.CrossRefGoogle ScholarPubMed
McNeer, K. W., Tucker, M. G., Guerry, C. H. and Spencer, R. F. (2003). Incidence of stereopsis after treatment of infantile esotropia with botulinum toxin A. J. Pediatr. Ophthalmol. Strabismus, 40(5), 288–92.Google ScholarPubMed
Campos, E. C., Schiavi, C. and Bellusci, C. (2000). Critical age of botulinum toxin treatment in essential infantile esotropia. J. Pediatr. Ophthalmol. Strabismus, 37(6), 328–32.Google ScholarPubMed
Tejedor, J. and Rodriguez, J. M. (1999). Early retreatment of infantile esotropia: comparison of reoperation and botulinum toxin. Br. J. Ophthalmol., 83(7), 783–7.CrossRefGoogle ScholarPubMed
Rayner, S. A., Hollick, E. J. and Lee, J. P. (1999). Botulinum toxin in childhood strabismus. Strabismus, 7(2), 103–11.CrossRefGoogle ScholarPubMed
Dawson, E. L., Marshman, W. E. and Adams, G. G. (1999). The role of botulinum toxin A in acute-onset esotropia. Ophthalmology, 106(9), 1727–30.CrossRefGoogle ScholarPubMed
Maurino, V., Kwan, A., Khoo, B. K., Gair, E. and Lee, J. P. (1998). Ocular motility disturbances after surgery for retinal detachment. J. AAPOS, 2(5), 285–92.CrossRefGoogle ScholarPubMed
Kikkawa, D. O., Cruz, R. C. Jr., Christian, W. K., Rikkers, S., Weinreb, R. N., Levi, L. and Granet, D. B. (2003). Botulinum A toxin injection for restrictive myopathy of thyroid-related orbitopathy: effects on intraocular pressure. Am. J. Ophthalmol., 135(4), 427–31.CrossRefGoogle ScholarPubMed
Ozkan, S. B., Kir, E., Dayanir, V. and Dundar, S. O. (2003). Botulinum toxin A in the treatment of adherence syndrome. Ophthalmic Surg. Lasers Imaging, 34(5), 391–5.Google ScholarPubMed
Repka, M. X., Lam, G. C. and Morrison, N. A. (1994). The efficacy of botulinum neurotoxin A for the treatment of complete and partially recovered chronic sixth nerve palsy. J. Pediatr. Ophthalmol. Strabismus, 31(2), 79–83.Google ScholarPubMed
Repka, M. X., Savino, P. J. and Reinecke, R. D. (1994). Treatment of acquired nystagmus with botulinum neurotoxin A. Arch. Ophthalmol., 112(10), 1320–4.CrossRefGoogle ScholarPubMed
Hallett, M. (2002). Blepharospasm: recent advances. Neurology, 59(9), 1306–12.CrossRefGoogle ScholarPubMed
Calace, P., Cortese, G., Piscopo, R., Della Volpe, G., Gagli, V., Magli, A. and Berardinis, T. (2003). Treatment of blepharospasm with botulinum neurotoxin type A: long-term results. Eur. J. Ophthalmol., 13(4), 331–6.CrossRefGoogle ScholarPubMed
Price, J., Farish, S., Taylor, H. and O'Day, J. (1997). Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections. Ophthalmology, 104(5), 865–8.CrossRefGoogle ScholarPubMed
Soylev, M. F., Kocak, N., Kuvaki, B., Ozkan, S. B. and Kir, E. (2002). Anesthesia with EMLA cream for botulinum A toxin injection into eyelids. Ophthalmologica, 216(5), 355–8.CrossRefGoogle ScholarPubMed
Muller, J., Kemmler, G., Wissel, J., Schneider, A., Voller, B., Grossman, J., Diez, J., Homann, N., Wenning, G. K., Schni, P. and Poewe, W. (2002). The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J. Neurol., 249(7), 842–6.Google ScholarPubMed
Groot, V., Wilde, F., Smet, L. and Tassignon, M. J. (2000). Frontalis suspension combined with blepharoplasty as an effective treatment for blepharospasm associated with apraxia of eye opening. Ophthal. Plast. Reconstr. Surg., 16(1), 34–8.CrossRefGoogle Scholar
Wang, A. and Jankovic, J. (1998). Hemifacial spasm: clinical findings and treatment. Muscle Nerve, 21(12), 1740–7.3.0.CO;2-V>CrossRefGoogle ScholarPubMed
Jitpimolmard, S., Tiamkao, S. and Laopaiboon, M. (1998). Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm report of 175 cases. J. Neurol. Neurosurg. Psychiatry, 64(6), 751–7.CrossRefGoogle ScholarPubMed
Sedano, M. J., Trejo, J. M., Macarron, J. L., Polo, J. M., Bercian, J. and Calleja, J. (2000). Continuous facial myokymia in multiple sclerosis treatment with botulinum toxin. Eur. Neurol., 43(3), 137–40.CrossRefGoogle ScholarPubMed
Ellis, M. F. and Daniell, M. (2001). An evaluation of the safety and efficacy of botulinum toxin type A (BOTOX) when used to produce a protective ptosis. Clin. Experiment. Ophthalmol., 29(6), 394–9.CrossRefGoogle ScholarPubMed
Steel, D. H., Hoh, H. B., Harrad, R. A. and Collins, C. R. (1997). Botulinum toxin for the temporary treatment of involutional lower lid entropion: a clinical and morphological study. Eye, 11, 472–5.CrossRefGoogle ScholarPubMed
Uddin, J. M. and Davies, P. D. (2002). Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection. Ophthalmology, 109(6), 1183–7.CrossRefGoogle ScholarPubMed
Montoya, F. J., Riddell, C. E., Caesar, R. and Hague, S. (2002). Treatment of gustatory hyperlacrimation (crocodile tears) with injection of botulinum toxin into the lacrimal gland. Eye, 16(6), 705–9.CrossRefGoogle ScholarPubMed
Whittaker, K. W., Matthews, B. N., Fitt, A. W. and Sandramouli, S. (2003). The use of botulinum toxin A in the treatment of functional epiphora. Orbit, 22(3), 193–8.CrossRefGoogle ScholarPubMed
Sahlin, S., Chen, E., Kaugesaar, T., Almqvist, H., Kjellberg, K. and Lennerstrand, G. (2000). Effect of eyelid botulinum toxin injection on lacrimal drainage. Am. J. Ophthalmol., 129(4), 481–6.CrossRefGoogle ScholarPubMed
Sherris, D. A. and Gassner, H. G. (2002). Botulinum toxin to minimize facial scarring. Facial Plast. Surg., 18(1), 35–9.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×